We focused on cancers that have high-level expression of MYCN and/or MYC in different instances, including retinoblastoma cells that co-express MYCN and MYC (RB176), neuroblastoma cells that highly express either MYCN (SK-N-BE(1)) or MYC (CHLA255, SH-SY5Y), SCLC cells that highly express either MYCN (H69, H526) or MYC (H211, H82), and SHH-like (DAOY, UW228-2) and Group 3 (D283, D341, D425) medulloblastoma lines for which only MYC-expressing lines are known (Table 1). This evidence concerns the gene MYCN and neuroblastoma.